GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

HLB Pharmaceutical Co 047920.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

7,220

-4.62%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩205.58bn

FY2016FY2025

Net income

₩4.57bn

FY2016FY2025

Free cash flow

−₩6.64bn

FY2016FY2025

Shareholders' equity

₩125.15bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩205.58bn₩137.08bn₩135.95bn₩107.48bn₩62.85bn₩40.57bn₩36.10bn₩20.54bn₩15.56bn₩20.35bn
Research and development₩3.34bn₩2.45bn₩2.31bn₩3.09bn₩2.52bn₩1.41bn—₩2.47bn₩2.74bn₩2.23bn
Operating income₩5.07bn₩1.36bn−₩5.44bn−₩6.42bn₩486.2m—₩1.00bn−₩5.41bn−₩4.37bn₩405.6m
Net income₩4.57bn₩2.02bn−₩19.43bn−₩11.78bn−₩13.23bn−₩74.84bn₩472.7m−₩7.06bn−₩5.45bn₩577.4m
Diluted earnings per share128.4566.63-640.91-422.55-506.78-3,565.3834.13-509.80-302.6448.77

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩170.68bn₩157.93bn₩141.35bn₩142.18bn₩127.63bn₩111.42bn₩46.39bn₩36.42bn₩39.85bn₩41.24bn
Cash and short-term investments—₩10.49bn₩25.87bn₩24.62bn₩25.54bn₩79.25bn₩14.04bn₩9.11bn₩11.00bn₩11.92bn
Total liabilities₩45.53bn₩41.53bn₩53.20bn₩56.25bn₩49.25bn₩66.80bn₩29.04bn₩19.42bn₩23.04bn₩22.34bn
Debt—₩16.05bn₩23.73bn₩26.35bn₩33.01bn₩40.25bn₩13.20bn₩7.69bn₩14.95bn₩15.15bn
Shareholders' equity₩125.15bn₩116.40bn₩88.15bn₩85.93bn₩78.38bn₩44.62bn₩17.36bn₩17.00bn₩16.80bn₩18.90bn
Shares outstanding36m30m30m28m26m21m14m14m18m12m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩569.0m₩6.84bn−₩18.32bn−₩2.76bn−₩1.32bn−₩403.4m₩1.35bn−₩1.78bn−₩784.3m−₩213.1m
Capital spending−₩7.21bn−₩3.09bn−₩4.26bn−₩2.90bn−₩49.51bn−₩2.98bn−₩1.40bn−₩1.10bn−₩2.24bn−₩4.77bn
Free cash flow−₩6.64bn₩3.75bn−₩22.57bn−₩5.66bn−₩50.83bn−₩3.38bn−₩43.8m−₩2.87bn−₩3.02bn−₩4.98bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩62.28bn₩65.65bn₩63.42bn₩60.59bn₩46.92bn₩34.65bn₩33.09bn₩34.77bn
Operating income₩60.8m₩778.7m₩834.8m₩34.1m−₩1.79bn₩1.99bn−₩1.23bn—
Net income−₩56.7m₩720.1m₩2.25bn−₩160.6m₩909.7m₩1.57bn₩2.18bn₩948.1m
Diluted earnings per share-1.5920.2363.34-4.5125.5645.4372.0631.28
Cash from operations₩775.0m₩587.0m₩1.10bn₩1.86bn−₩1.32bn−₩1.07bn₩6.84bn₩6.27bn
Capital spending−₩1.05bn−₩2.82bn−₩2.50bn−₩2.25bn−₩2.03bn−₩431.0m−₩3.09bn−₩2.17bn
Free cash flow−₩271.0m−₩2.23bn−₩1.40bn−₩391.0m−₩3.35bn−₩1.50bn₩3.75bn₩4.10bn
Total assets₩178.03bn₩202.65bn₩170.68bn₩167.93bn₩162.98bn₩144.60bn₩157.93bn₩160.07bn
Cash and short-term investments——————₩10.49bn₩36.09bn
Debt——————₩15.29bn₩15.40bn
Shareholders' equity₩130.76bn₩151.73bn₩125.15bn₩120.95bn₩122.81bn₩109.10bn₩116.40bn₩119.48bn

Financial ratios

Data as of 1 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2017
Operating margin2.5%1.0%-4.0%-6.0%0.8%—4.0%—
Net margin2.2%1.5%-14.3%-11.0%-21.0%-184.5%——
Return on equity3.7%1.7%-22.0%-13.7%-16.9%-167.7%——
Return on assets2.7%1.3%-13.7%-8.3%-10.4%-67.2%——
Free cash flow yield———————1.0%
Revenue growth50.0%0.8%26.5%71.0%54.9%12.4%——
Earnings growth126.3%-110.4%65.0%-11.0%-82.3%-15934.1%——
Current ratio1.94x1.64x1.46x1.13x1.13x1.53x——
Debt to equity—0.13x0.06x0.00x0.00x0.04x0.16x—
Equity ratio73.3%73.7%62.4%60.4%61.4%40.0%——
Interest coverage6.87x2.18x-0.46x-1.28x0.03x———
R&D as a share of sales1.6%1.8%1.7%2.9%4.0%3.5%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue24.1%38.3%27.8%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin1.9%-0.9%——
Net margin1.9%-4.2%-16.3%-15.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings124.9361.7-23.7-25.1-26.6-4.8159.1-8.3-21.2106.4
Price to sales2.85.33.42.85.68.82.12.97.43.0

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 3-for-2 split · 12 Apr 2016

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.